ARCHIVES

Guest Editorial: Omics Checklist Done, Now Create Business Model For Tests

This article is from The Cancer Letter archive.

Vol. 39 No. 06 | February 7, 2013

Download PDF Visit The Full Archive

Related Articles

NIH To Site Visit Animal Facilities

March 18, 1983

Also R01 payline likely to fall below 20th percentile in FY04.

September 26, 2003

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013

In Brief: FY 1985 Budget Breakdown; Control Gets $64 Million, Construction $6.5; W. VA. $4.5 Maybe

November 9, 1984

Sentinel Node Disection No Worse Than Axillary

February 25, 2011

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

July 27, 2012